Asam Bempedoat Untuk Dislipidemia

Oleh :

dr.I.B. Komang Arjawa, Sp.JP, FIHA

Penggunaan asam bempedoat atau bempedoic acid dilaporkan efektif dalam menangani dislipidemia dan hiperkolesterolemia. Pada umumnya, asam bempedoat digunakan sebagai terapi adjuvan terhadap diet dan statin pada pasien dengan dislipidemia untuk menurunkan risiko atherosclerotic cardiovascular disease (ASCVD) yang meliputi infark miokard dan stroke iskemik.[1,2]

Penelitian telah menunjukkan bahwa peningkatan LDL (low-density lipoprotein) adalah salah satu faktor risiko utama dari ASCVD. Penurunan LDL 1 mmol/L (setara dengan 40 mg/dl) mampu menurunkan risiko kejadian ASCVD sebanyak 22%. Selama ini, pengobatan pilihan pada dislipidemia adalah menggunakan golongan statin. Namun, banyak pasien tidak mampu mentoleransi statin, dimana mayoritas kejadian intoleransi tersebut disebabkan oleh gangguan otot.[2]

Permasalahan dalam Tata Laksana Dislipidemia

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opinion on Investigational Drugs. 2017 Feb;26(2):251–9.
2. Attardo S, Musumeci O, Velardo D, Toscano A. Statins Neuromuscular Adverse Effects. Int J Mol Sci. 2022 Jul 28;23(15):8364. doi: 10.3390/ijms23158364. PMID: 35955495; PMCID: PMC9369175.
3. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. JAHA, 2019; 8(7). https://www.ahajournals.org/doi/10.1161/JAHA.118.011662
4. Feng X, Zhang L, Xu S, Shen A. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Progress in Lipid Research. 2020; 77: 101006.
5. Ruscica M, Sirtori CR, Carugo S, Banach M, Corsini A. Bempedoic Acid : for Whom and When. Current Atherosclerosis Reports. 2022; 24:791-801
6. Tummala R, Gupta M, Devanabanda AR, Bandyopadhyay D, Aronow WS, Ray KK, Mamas M, Ghosh RK. Bempedoic Acid and Its Role in Contemporary Management of Hyperlipidemia in Atherosclerosis. Ann Med. 2022; 54(1): 1287-1296
7. Minno AD, Lupoli R, Calcaterra I, Poggio P, Forte F, Spadarella G, Ambrosino P, Lannuzzo G, Nicola M, Minno DD. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2020; 4;9(15):e016262
8. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med.2019; 380: 1022-1032
9. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, et al. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019 Nov 12;322(18):1780.
10. US National Library of Medicine. Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes). Clinical Trials Gov, 2020. https://clinicaltrials.gov/ct2/show/NCT02993406